JP2016530268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530268A5 JP2016530268A5 JP2016535272A JP2016535272A JP2016530268A5 JP 2016530268 A5 JP2016530268 A5 JP 2016530268A5 JP 2016535272 A JP2016535272 A JP 2016535272A JP 2016535272 A JP2016535272 A JP 2016535272A JP 2016530268 A5 JP2016530268 A5 JP 2016530268A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- inhibitor
- use according
- mammal
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 claims 25
- 102100035268 T-cell surface protein tactile Human genes 0.000 claims 25
- 239000003112 inhibitor Substances 0.000 claims 15
- 241000124008 Mammalia Species 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 102000016844 Immunoglobulin-like domains Human genes 0.000 claims 6
- 108050006430 Immunoglobulin-like domains Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 108010074328 Interferon-gamma Proteins 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 101100098678 Homo sapiens CD96 gene Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000013461 design Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000010353 genetic engineering Methods 0.000 claims 2
- 230000008629 immune suppression Effects 0.000 claims 2
- 230000037451 immune surveillance Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 108700012434 CCL3 Proteins 0.000 claims 1
- 102000000013 Chemokine CCL3 Human genes 0.000 claims 1
- 102000001326 Chemokine CCL4 Human genes 0.000 claims 1
- 108010055165 Chemokine CCL4 Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903189A AU2013903189A0 (en) | 2013-08-22 | Immunomodulator | |
| AU2013903189 | 2013-08-22 | ||
| AUPCT/AU2013/001132 | 2013-10-03 | ||
| PCT/AU2013/001132 WO2015024042A1 (en) | 2013-08-22 | 2013-10-03 | Immunoreceptor modulation for treating cancer and viral infections |
| AU2014900741A AU2014900741A0 (en) | 2014-03-05 | Immunoreceptor modulation for treating cancer and viral infections | |
| AU2014900741 | 2014-03-05 | ||
| AU2014901002A AU2014901002A0 (en) | 2014-03-21 | Immunoreceptor modulation for treating cancer and viral infections | |
| AU2014901002 | 2014-03-21 | ||
| PCT/AU2014/000830 WO2015024060A1 (en) | 2013-08-22 | 2014-08-22 | Immunoreceptor modulation for treating cancer and viral infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205385A Division JP2020059714A (ja) | 2013-08-22 | 2019-11-13 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530268A JP2016530268A (ja) | 2016-09-29 |
| JP2016530268A5 true JP2016530268A5 (enExample) | 2017-10-05 |
| JP6618908B2 JP6618908B2 (ja) | 2019-12-11 |
Family
ID=52482836
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535272A Active JP6618908B2 (ja) | 2013-08-22 | 2014-08-22 | 免疫抑制を低減又は軽減するためのcd96阻害抗体又は抗体断片の使用 |
| JP2019205385A Pending JP2020059714A (ja) | 2013-08-22 | 2019-11-13 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| JP2022012145A Pending JP2022044808A (ja) | 2013-08-22 | 2022-01-28 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| JP2023134163A Pending JP2023156487A (ja) | 2013-08-22 | 2023-08-21 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205385A Pending JP2020059714A (ja) | 2013-08-22 | 2019-11-13 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| JP2022012145A Pending JP2022044808A (ja) | 2013-08-22 | 2022-01-28 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
| JP2023134163A Pending JP2023156487A (ja) | 2013-08-22 | 2023-08-21 | 癌及びウイルス感染症を治療するための免疫受容体調節 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20160208000A1 (enExample) |
| EP (1) | EP3036258B1 (enExample) |
| JP (4) | JP6618908B2 (enExample) |
| KR (3) | KR20230085220A (enExample) |
| CN (1) | CN105636985A (enExample) |
| BR (1) | BR112016003532A8 (enExample) |
| CA (1) | CA2921774C (enExample) |
| DK (1) | DK3036258T3 (enExample) |
| ES (1) | ES2967538T3 (enExample) |
| FI (1) | FI3036258T3 (enExample) |
| HK (1) | HK1225396A1 (enExample) |
| HR (1) | HRP20231186T1 (enExample) |
| HU (1) | HUE063307T2 (enExample) |
| MX (1) | MX2016002263A (enExample) |
| MY (1) | MY192043A (enExample) |
| NZ (1) | NZ717534A (enExample) |
| PL (1) | PL3036258T3 (enExample) |
| SG (1) | SG11201601283PA (enExample) |
| SI (1) | SI3036258T1 (enExample) |
| WO (1) | WO2015024060A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013398294A1 (en) * | 2013-08-22 | 2016-03-17 | The Council Of The Queensland Institute Of Medical Research | Immunoreceptor modulation for treating cancer and viral infections |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| CA2942245C (en) | 2014-03-12 | 2021-11-02 | Yeda Research And Development Co. Ltd. | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| KR102644115B1 (ko) | 2014-12-23 | 2024-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | Tigit에 대한 항체 |
| ES2939084T3 (es) * | 2015-07-29 | 2023-04-18 | Onk Therapeutics Ltd | Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada |
| CA2993432A1 (en) | 2015-09-01 | 2017-03-09 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| RS63125B1 (sr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
| IL263834B2 (en) | 2016-06-20 | 2024-01-01 | Kymab Ltd | Anti-pd-l1 antibodies |
| BR112019011582A2 (pt) | 2016-12-07 | 2019-10-22 | Agenus Inc. | anticorpos e métodos de utilização dos mesmos |
| EP3664843A1 (en) * | 2017-08-11 | 2020-06-17 | BliNK Biomedical SAS | Cd96-binding agents as immunomodulators |
| US20200347130A1 (en) * | 2017-11-10 | 2020-11-05 | Jiangsu Hengrui Medicine Co., Ltd. | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| KR20220053007A (ko) * | 2019-08-30 | 2022-04-28 | 아게누스 인코포레이티드 | 항-cd96 항체 및 이의 사용 방법 |
| EP4034562B1 (en) * | 2019-09-27 | 2025-10-29 | GlaxoSmithKline Intellectual Property Development Limited | Antigen binding proteins |
| EP4052727A4 (en) * | 2019-10-30 | 2023-12-20 | University of Tsukuba | IMMUNE RESPONSE INHIBITOR |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
| CN116377061B (zh) * | 2022-11-28 | 2024-01-16 | 中山大学孙逸仙纪念医院 | 乳腺癌新辅助化疗耐药标志物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1481993A1 (en) * | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation of the poliovirus receptor function |
| WO2005107799A1 (ja) * | 2004-05-06 | 2005-11-17 | Eisai R & D Management Co., Ltd. | 抗Necl-5抗体を有効成分として含む癌治療剤 |
| EP2097535B1 (en) * | 2006-12-07 | 2016-09-21 | The Board of Trustees of the Leland Stanford Junior University | Identification and isolation of acute myeloid leukemia stem cells |
| SG10202112838YA (en) * | 2008-04-09 | 2021-12-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
| US9149544B2 (en) * | 2009-11-06 | 2015-10-06 | The Penn State Research Foundation | Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo |
| CN102204901A (zh) * | 2010-03-30 | 2011-10-05 | 中国科学院上海生命科学研究院 | 调节免疫分子的试剂和方法 |
| HK1210964A1 (en) * | 2012-12-04 | 2016-05-13 | Oncomed Pharmaceuticals, Inc. | Immunotherapy with binding agents |
| CN105378067A (zh) * | 2013-05-13 | 2016-03-02 | 塞勒克提斯公司 | 工程化用于免疫治疗的高活性t细胞的方法 |
-
2014
- 2014-08-22 SI SI201432042T patent/SI3036258T1/sl unknown
- 2014-08-22 BR BR112016003532A patent/BR112016003532A8/pt not_active Application Discontinuation
- 2014-08-22 DK DK14838641.0T patent/DK3036258T3/da active
- 2014-08-22 MX MX2016002263A patent/MX2016002263A/es unknown
- 2014-08-22 FI FIEP14838641.0T patent/FI3036258T3/fi active
- 2014-08-22 JP JP2016535272A patent/JP6618908B2/ja active Active
- 2014-08-22 EP EP14838641.0A patent/EP3036258B1/en active Active
- 2014-08-22 CN CN201480052069.7A patent/CN105636985A/zh active Pending
- 2014-08-22 CA CA2921774A patent/CA2921774C/en active Active
- 2014-08-22 KR KR1020237018788A patent/KR20230085220A/ko not_active Ceased
- 2014-08-22 HU HUE14838641A patent/HUE063307T2/hu unknown
- 2014-08-22 KR KR1020167007435A patent/KR20160055819A/ko not_active Ceased
- 2014-08-22 HK HK16113673.9A patent/HK1225396A1/zh unknown
- 2014-08-22 MY MYPI2016000314A patent/MY192043A/en unknown
- 2014-08-22 SG SG11201601283PA patent/SG11201601283PA/en unknown
- 2014-08-22 KR KR1020257003382A patent/KR20250024106A/ko active Pending
- 2014-08-22 HR HRP20231186TT patent/HRP20231186T1/hr unknown
- 2014-08-22 US US14/913,348 patent/US20160208000A1/en not_active Abandoned
- 2014-08-22 ES ES14838641T patent/ES2967538T3/es active Active
- 2014-08-22 PL PL14838641.0T patent/PL3036258T3/pl unknown
- 2014-08-22 WO PCT/AU2014/000830 patent/WO2015024060A1/en not_active Ceased
- 2014-08-22 NZ NZ717534A patent/NZ717534A/en unknown
-
2019
- 2019-11-13 JP JP2019205385A patent/JP2020059714A/ja active Pending
-
2020
- 2020-07-24 US US16/938,214 patent/US20210047403A1/en active Pending
-
2022
- 2022-01-28 JP JP2022012145A patent/JP2022044808A/ja active Pending
-
2023
- 2023-08-21 JP JP2023134163A patent/JP2023156487A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530268A5 (enExample) | ||
| JP2016530267A5 (enExample) | ||
| Vangelista et al. | The expanding therapeutic perspective of CCR5 blockade | |
| Utsunomiya et al. | Recent advances in the treatment of adult T‐cell leukemia‐lymphomas | |
| HRP20231186T1 (hr) | Modulacija imunoreceptora za liječenje raka i virusnih infekcija | |
| Michlmayr et al. | Defining the chemokine basis for leukocyte recruitment during viral encephalitis | |
| WO2014089169A4 (en) | Immunotherapy with binding agents | |
| MX2024002353A (es) | Celulas asesinas naturales modificadas geneticamente. | |
| MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
| JP2017513478A5 (enExample) | ||
| NZ601943A (en) | Antibodies against cxcr4 | |
| JP2018522592A5 (enExample) | ||
| MX2020012416A (es) | Anticuerpos dirigidos contra il-33 y sus usos. | |
| WO2018191548A3 (en) | Complement factor d antagonist antibodies and conjugates thereof | |
| JP2014530226A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| JP2019520550A5 (enExample) | ||
| EA201200795A1 (ru) | Связывающие элементы для пептида с5а с высоким ингибирующим действием | |
| MX2017009052A (es) | Anticuerpos de unión a april modificados. | |
| MX2021001305A (es) | Anticuerpos anti-cxcr2 y usos de los mismos. | |
| JP2014087372A5 (enExample) | ||
| GB2496337A (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
| TN2015000348A1 (en) | Antibodies that bind il-23 | |
| CN111542546A (zh) | 抗lag-3 抗体及其用途 | |
| JP2017521445A5 (enExample) |